Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed , Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined
Pronunciation: dif-THEER-ee-a/TET-a-nus/aye-SELL-yoo-ler per-TUS-is/hep-a-TYE-tis/POE-lee-oh-VYE-rus
Class: Vaccine combination
- Injection, suspension diphtheria toxoid (DT) 25 Lf, tetanus toxoid 10 Lf, inactivated pertussis toxin (PT) 25 mcg, filamentous hemagglutinin (FHA) 25 mcg, pertactin 8 mcg, hepatitis B surface antigen (HBsAg) 10 mcg, type 1 poliovirus 40 D-antigen units (DU), type 2 poliovirus 8 DU, and type 3 poliovirus 32 DU per 0.5 mL
Diphtheria and tetanus toxoids induce antibodies against toxins made by Corynebacterium diphtheriae and Clostridium tetani ; pertussis vaccine protects against Bordetella pertussis ; hepatitis B vaccine induces specific antibodies against hepatitis B virus (HBV); poliovirus vaccine induces protective antipoliovirus antibodies, reducing pharyngeal excretion of poliovirus types 1, 2, and 3.
Indications and Usage
For active immunization against diphtheria, tetanus, pertussis, all known subtypes of HBV, and poliomyelitis (caused by types 1, 2, and 3) as a 3-dose primary series in infants born of HBsAg-negative mothers, beginning as early as 6 wk of age.
Use of this vaccine after a serious allergic reaction temporally associated with a previous dose of the vaccine or with any components of this vaccine; encephalopathy (eg, coma, decreased level of consciousness, prolonged seizures) within 7 days of administration of a previous dose of a pertussis-containing vaccine not attributable to another identifiable cause; progressive neurologic disorder (including infantile spasms, progressive encephalopathy, or uncontrolled epilepsy); hypersensitivity to any component of the vaccine (including neomycin, polymyxin B, and yeast).
Dosage and AdministrationChildren Previously Vaccinated With Hepatitis B Vaccine
Children born of HBsAg-negative mothers who have received a dose of hepatitis B at or shortly after birth
IM 3 doses of 0.5 mL according to the recommended schedule.Children Previously Vaccinated With Inactivated Poliovirus Vaccine (IPV)
IM Pediarix may be used to complete the first 3 doses of the IPV series in infants who have received 1 or 2 doses of IPV and who are also scheduled to receive the other vaccine components of Pediarix .Children Previously Vaccinated With Infanrix
IM Pediarix may be used to complete the first 3 doses of the diphtheria and tetanus toxoids and acellular pertussis (DTaP) series in infants who have received 1 or 2 doses of Infanrix and also are scheduled to receive the other vaccine components of Pediarix .Immunization
Children 6 wk through 6 y of age
IM 3 doses of 0.5 mL at 6- to 8-wk intervals (preferably 8 wk). Customary age for the first dose is 2 mo.Interchangeability of Licensed DTaP, IPV, or Recombinant Hepatitis B Vaccines and Pediarix
It is recommended that Pediarix be given for all 3 doses because data are limited regarding the safety and efficacy of using acellular pertussis vaccines from different manufacturers for successive doses of the pertussis vaccination series. Because of a lack of data, Pediarix is not recommended for completion of a DTaP vaccination series initiated with a DTaP vaccine from a different manufacturer. However, Pediarix may be used to complete hepatitis B vaccination series initiated with a licensed hepatitis B (recombinant) vaccine from a different manufacturer and may be used complete the first 3 doses of the IPV vaccination series initiated with IPV from a different manufacturer.
- If any recommended dose of pertussis vaccine cannot be given, DT (for pediatric use), hepatitis B (recombinant), and IPV should be given as needed to complete the series. Children who have received a 3-dose primary series of Pediarix should be given a fourth dose of IPV at 4 to 6 y of age and a fourth dose of DTaP vaccine at 15 to 18 mo of age.
- For IM injection only. Do not administer subcutaneously, IV, or intradermally.
- Shake vigorously to obtain a homogeneous, turbid, white suspension before preparing dose. Do not use if resuspension does not occur with vigorous shaking.
- Interruption of the recommended schedule with a delay between doses does not interfere with development of final immunity. There is no need to start the series over again.
- Administer IM in anterolateral thigh in infants or the deltoid muscle of the upper arm in toddlers and young children. Avoid injection into gluteal area or areas where there may be a major nerve trunk or blood vessel. Gluteal injections may result in a suboptimal hepatitis B immune response.
- When coadministration of other vaccines is required, they should be given with separate syringes and at different injection sites.
- Do not mix with any other vaccines in the same syringe or vial.
- Take special care to prevent injection into a blood vessel.
- Use separate syringes and different sites for coadministration of other vaccines.
- Always record manufacturer's name and vaccine lot number in patient's permanent medical record file along with the date of administration and name and title of person administering vaccine.
Refrigerate between 36° and 46°F. Do not freeze. Discard if vaccine has been frozen. Discard any vaccine remaining in the vial after administration.
Drug InteractionsImmunosuppressive agents (alkylating agents, antimetabolites, corticosteroids [at greater than physiologic doses], cytotoxic agents, irradiation therapy)
Children may not respond optimally to active immunization.Other vaccines
Do not mix another vaccine in the same syringe or vial.
Irritability/fussiness (65%); drowsiness (57%); brachial neuritis; cranial and peripheral mononeuropathy; demyelinating diseases of the CNS; bulging fontanelle, convulsions, crying, depressed consciousness, fatigue, febrile convulsions, hypotonia, hypotonic-hyporesponsive episode, insomnia, irritability, lethargy, nervousness, restlessness, screaming, somnolence, unusual crying (postmarketing).
Cyanosis, erythema, pallor, petechiae, rash, urticaria (postmarketing).
Loss of appetite (31%); anorexia, diarrhea, vomiting (postmarketing).
Anaphylactic reactions (ie, difficulty breathing, hives, hypotension, shock, swelling of the mouth); Arthus-type hypersensitivity reactions characterized by severe local reactions; anaphylactoid reactions, angioedema (postmarketing).
Redness (40%); pain (36%); swelling (29%); induration, injection-site cellulitis, itching, nodules/lumps, vesicles, and warmth (postmarketing).
Apnea, cough, dyspnea, upper respiratory tract infection (postmarketing).
Fever (39%); abnormal LFTs, limb pain and swelling, sudden infant death syndrome (postmarketing).
Category C . Not indicated for use in women of childbearing age.
Not indicated for use in women of childbearing age.
Safety and efficacy not established in children younger than 6 wk of age. Pediarix is not recommended for persons 7 y of age and older.
Not indicated for use in the adult population.
Acute febrile illness
Consider delaying immunization during course of moderate or severe acute febrile illness.
Epinephrine solution (1:1000) and other appropriate agents and equipment must be available for immediate use in case of occurrence of an anaphylactic or acute hypersensitivity reaction.
Use with caution in children with bleeding disorders (eg, hemophilia, thrombocytopenia) and in children on anticoagulant therapy; take steps to avoid the risk of hematoma following the injection.
The decision to administer a pertussis-containing vaccine to children with stable CNS disorders must be made with consideration to the risks and benefits for that child. The Advisory Committee on Immunization Practices has issued guidelines for such children.
If Guillain-Barré syndrome occurred within 6 wk of receiving a prior vaccine containing tetanus toxoid, base the decision to give Pediarix vaccine or any vaccine containing tetanus toxoid on careful consideration of potential benefits and possible risks.
The expected immune response may not be obtained.
The tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber that may cause allergic reactions in latex-sensitive individuals.
If any of the reactions occur after receipt of acellular pertussis, the decision to give any pertussis vaccine should be based on careful consideration of the risks and benefits: temperature of 105°F within 48 h not attributable to an identifiable cause; collapse or shock-like state within 48 h; persistent, inconsolable crying lasting at least 3 h and occurring with 48 h; seizures with or without fever occurring within 3 days.
For infants and children at risk of seizures, an appropriate antipyretic may be administered at the time of vaccination and for the following 24 h to reduce possible postvaccination fever.
- Provide and review vaccine information sheet prior to immunization.
- Review immunization schedule and advise parent or guardian that the entire series must be completed to provide maximum benefit.
- Provide parent or guardian with immunization history record.
- Inform parents or guardian that children with a minor illness, such as a cold, may be vaccinated. Wait to vaccinate children who are moderately or severely ill until after they recover.
- Advise parent or guardian to contact their child's health care provider immediately if the child develops a high temperature (105°F or higher) within 48 hours of vaccination; a collapse or shock-like state within 48 hours of vaccination; persistent crying lasting 3 hours or more within 48 hours of vaccination; seizures with or without a fever within 3 days of vaccination; or changes in mental alertness or unresponsiveness within 7 days of receiving this vaccine.
- Advise parent or guardian to use nonaspirin-containing OTC analgesics (eg, acetaminophen, ibuprofen) for fever, pain, or discomfort at injection site.
- Advise parent or guardian to notify health care provider if bothersome adverse reactions last more than 24 h.
Copyright © 2009 Wolters Kluwer Health.